Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039384 · ClinicalTrials.gov registry record · Phase 1
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT06039384 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 6 participants.
The verdict
NCT06039384, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
Interventions
- DRUG INCB099280
- DRUG adagrasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2025-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06039384
The ClinicalTrials.gov registry entry for NCT06039384 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INCB099280 is the first listed.
NCT06039384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06039384 about?
NCT06039384 is a clinical study titled "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation". The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
What is the current status of trial NCT06039384?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-12-28. Estimated completion is 2025-07-11.
What interventions are being tested in trial NCT06039384?
The interventions under investigation include: INCB099280 (DRUG), adagrasib (DRUG).
Who is sponsoring clinical trial NCT06039384?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.